Welcome to DU! The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards. Join the community: Create a free account Support DU (and get rid of ads!): Become a Star Member Latest Breaking News General Discussion The DU Lounge All Forums Issue Forums Culture Forums Alliance Forums Region Forums Support Forums Help & Search

EarlG

(21,945 posts)
Tue Aug 24, 2021, 08:01 PM Aug 2021

Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial

This is new — a friend of mine just sent it to me. Looks promising…

The monoclonal antibody combination therapy reduced the combined endpoint of hospitalizations and death by 78% over placebo in 837 COVID-19 patients at high risk of clinical progression.

These data demonstrate that high-risk outpatients may benefit from combination BRII-196/BRII-198 therapy up to 10 days following symptom onset.

https://www.briibio.com/news-detial.php?id=328#news
1 replies = new reply since forum marked as read
Highlight: NoneDon't highlight anything 5 newestHighlight 5 most recent replies
Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial (Original Post) EarlG Aug 2021 OP
That success rate might be might be high enough viva la Aug 2021 #1

viva la

(3,286 posts)
1. That success rate might be might be high enough
Tue Aug 24, 2021, 08:34 PM
Aug 2021

That they'll call the placebo phase over and go right to prescribing it. You don't really want to give people placebos when you could save their life with a drug combo like this.

If they've established it's safe, they might shift to comparing 2 different doses so everyone in the trial gets the med. I Wasn't a trial like that period the drug was shown to be so effective, they ma'am they stopped the placebo a placebo phase and went right to dose comparison. I was in a trial like that. The drug was shown to be so effective, they stopped the placebo phase and went right to dose comparison.

Latest Discussions»Issue Forums»Health»Brii Biosciences Announce...